Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Justin Faden. (2019) How do we select an antipsychotic for those with schizophrenia?. Expert Opinion on Pharmacotherapy 20:18, pages 2195-2199.
Read now
Read now
Fernanda S Tonin, Astrid Wiens, Fernando Fernandez-Llimos & Roberto Pontarolo. (2016) Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. Core Evidence 11, pages 49-61.
Read now
Read now
Roberto Mandrioli, Michele Protti & Laura Mercolini. (2015) Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder. Expert Opinion on Drug Metabolism & Toxicology 11:1, pages 149-174.
Read now
Read now
Istvan M. Majer, Fiona Gaughran, Christophe Sapin, Maud Beillat & Maarten Treur. (2015) Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. Journal of Market Access & Health Policy 3:1.
Read now
Read now
Leslie Citrome. (2013) New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Review of Neurotherapeutics 13:7, pages 767-783.
Read now
Read now
Articles from other publishers (40)
Nicolette Stogios, Kateryna Maksyutynska, Janani Navagnanavel, Marcos Sanches, Valerie Powell, Philip Gerretsen, Ariel Graff‐Guerrero, Araba F. Chintoh, George Foussias, Gary Remington, Margaret K. Hahn & Sri Mahavir Agarwal. (2022) Metformin for the prevention of clozapine‐induced weight gain: A retrospective naturalistic cohort study. Acta Psychiatrica Scandinavica 146:3, pages 190-200.
Crossref
Crossref
Gerd Laux. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
11
.
Gerd Laux. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
11
.
Gerd Laux. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
11
.
Peter SturmeyPeter Sturmey. 2022. Violence and Aggression. Violence and Aggression
441
474
.
Gerd Laux. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1837
1846
.
Gerd Laux. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1859
1869
.
Gerd Laux. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1847
1857
.
Syed Idrees Hassan SajjadDandu Venkata Satya Sanjay Varma. (2021) OLANZAPINE POISONING IN CHILDREN : A CASE SERIES. INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, pages 32-33.
Crossref
Crossref
María Recio-Barbero, Rafael Segarra, Arantzazu Zabala, Eduardo González-Fraile, Ana González-Pinto & Javier Ballesteros. (2021) Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms. Frontiers in Psychiatry 12.
Crossref
Crossref
Bhanu Gupta, Kok-Seng Chee, Li-Qi Neo, Charmaine Tang, Jayaraman Hariram, Geoffrey Chern-Yee Tan, Swapna Verma, Sutapa Basu, Deva-Priya Appan, Chan-Chun Ting, Edimansyah Abdin & Jimmy Lee. (2021) Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial. Therapeutic Advances in Psychopharmacology 11, pages 204512532110467.
Crossref
Crossref
Hamzah Bakouni & Helen-Maria Vasiliadis. (2019) Off-Label Use of Antipsychotics and Health Related Quality of Life in Community Living Older Adults. Applied Research in Quality of Life 15:4, pages 991-1004.
Crossref
Crossref
Jan Jaracz. (2020) Polytherapy in schizophrenia in light of the literature data. Pharmacotherapy in Psychiatry and Neurology 35:3-4, pages 193-199.
Crossref
Crossref
Deanna L. Kelly & Raymond C. Love. (2019) Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management. Mental Health Clinician 9:2, pages 64-69.
Crossref
Crossref
Susanne Mudra, Daniel Luedecke, Maria Grafmann & Michael Schulte-Markwort. (2018) Myocarditis During Treatment With Clozapine in 2 Adolescent Cases. Journal of Clinical Psychopharmacology 38:6, pages 639-640.
Crossref
Crossref
Borja Santos, Eduardo González-Fraile, Arantzazu Zabala, Virginia Guillén, José R Rueda & Javier Ballesteros. (2018) Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. Journal of Psychopharmacology 32:11, pages 1155-1166.
Crossref
Crossref
Claire Ainsworth. (2018) Assessing the robustness of direct meta-analysis in the presence of heterogeneity. Journal of Comparative Effectiveness Research 7:10, pages 1009-1025.
Crossref
Crossref
Dhinesh Kumar Thiyagarajamoorthy, Charli Deepak Arulanandam, Hans-Uwe Dahms, Santhosh Gokul Murugaiah, Muthukumar Krishnan & Arthur James Rathinam. (2018) Marine Bacterial Compounds Evaluated by In Silico Studies as Antipsychotic Drugs Against Schizophrenia. Marine Biotechnology 20:5, pages 639-653.
Crossref
Crossref
Stephanie Lock Man Lung, Ho Ming Edwin Lee, Yu Hai Eric Chen, Kit Wa Sherry Chan, Wing Chung Chang & Lai Ming Christy Hui. (2018) Prevalence and correlates of antipsychotic polypharmacy in Hong Kong. Asian Journal of Psychiatry 33, pages 113-120.
Crossref
Crossref
Kathleen Patchan, Gopal Vyas, Ann L. Hackman, Marie Mackowick, Charles M. Richardson, Raymond C. Love, Ikwunga Wonodi, MacKenzie A. Sayer, Matthew Glassman, Stephanie Feldman & Deanna L. Kelly. (2017) Clozapine in Reducing Aggression and Violence in Forensic Populations. Psychiatric Quarterly 89:1, pages 157-168.
Crossref
Crossref
Sabina Abidi, Irfan Mian, Iliana Garcia-Ortega, Tania Lecomte, Thomas Raedler, Kevin Jackson, Kim Jackson, Tamara Pringsheim & Donald Addington. (2017) Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth. The Canadian Journal of Psychiatry 62:9, pages 635-647.
Crossref
Crossref
Jaime M. Monti, Pablo Torterolo & Seithikurippu R. Pandi Perumal. (2017) The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep Medicine Reviews 33, pages 51-57.
Crossref
Crossref
Jaime M. Monti, Pablo Torterolo & Seithikurippu R. Pandi Perumal. 2016. Dopamine and Sleep. Dopamine and Sleep
213
233
.
Frederik J. R. Rombouts, Fulgencio Tovar, Nigel Austin, Gary Tresadern & Andrés A. Trabanco. (2015) Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example. Journal of Medicinal Chemistry 58:23, pages 9287-9295.
Crossref
Crossref
Gregory Kruse, Bruce J. O. Wong, Mei Sheng Duh, Patrick Lefebvre, Marie-Hélène Lafeuille & John M. Fastenau. (2015) Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment. PharmacoEconomics 33:10, pages 1049-1067.
Crossref
Crossref
Saeed Shoja Shafti & Hamid Kaviani. (2015)
Quetiapine
versus
aripiprazole in the management of schizophrenia
. Therapeutic Advances in Psychopharmacology 5:3, pages 166-171.
Crossref
Crossref
Gabrielle Crépeau-Gendron & Sophie L'Heureux. (2015) Quetiapine XR-induced neutropenia: is a clozapine trial still possible for treatment-resistant schizophrenia? A case report. Early Intervention in Psychiatry 9:2, pages 151-155.
Crossref
Crossref
Jingxia Lin, Edwin Ho-Ming Lee, Chun-Yat Tong, Jenny Tsui-Man Lee & Eric Yu-Hai Chen. (2014) Therapeutic potentials of mind–body interventions for psychosis. Clinical Practice 11:6, pages 677-688.
Crossref
Crossref
Merja Viikki, Olli Kampman, Niko Seppälä, Nina Mononen, Terho Lehtimäki & Esa Leinonen. (2014) CYP1A2polymorphism −1545C > T (rs2470890) is associated with increased side effects to clozapine. BMC Psychiatry 14:1.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2014) Clozapine oral suspension (Versacloz™): a guide to its use in the USA. Drugs & Therapy Perspectives 30:6, pages 193-199.
Crossref
Crossref
J Liu, A Ogden, TA Comery, A Spiros, P Roberts & H Geerts. (2014)
Prediction of Efficacy of Vabicaserin, a 5‐HT
2C
Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model
. CPT: Pharmacometrics & Systems Pharmacology 3:4, pages 1-8.
Crossref
Crossref
C. Schneider, R. Corrigall, D. Hayes, M. Kyriakopoulos & S. Frangou. (2020) Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia. European Psychiatry 29:1, pages 1-10.
Crossref
Crossref
Naomi R. Wray, Enda M. Byrne, Sven Stringer & Bryan J. Mowry. 2014. Behavior Genetics of Psychopathology. Behavior Genetics of Psychopathology
311
337
.
M M Söderberg, T Haslemo, E Molden & M-L Dahl. (2012) Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. The Pharmacogenomics Journal 13:6, pages 544-550.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2013) Oral olanzapine: a guide to its use in adults with schizophrenia or bipolar I disorder. Drugs & Therapy Perspectives 29:10, pages 291-296.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2013) Clozapine: a guide to its use in patients with schizophrenia who are unresponsive to or intolerant of other antipsychotic agents. Drugs & Therapy Perspectives 29:6, pages 161-165.
Crossref
Crossref
Qingqing Xu, Xi Wu, Yuyu Xiong, Qinghe Xing, Lin He & Shengying Qin. (2013) Pharmacogenomics can improve antipsychotic treatment in schizophrenia. Frontiers of Medicine 7:2, pages 180-190.
Crossref
Crossref
Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe & Masaru Mimura. 2013. Polypharmacy in Psychiatry Practice, Volume II. Polypharmacy in Psychiatry Practice, Volume II
81
107
.
Otto Benkert & Hanns HippiusOtto Benkert & Hanns Hippius. 2013. Kompendium der Psychiatrischen Pharmakotherapie. Kompendium der Psychiatrischen Pharmakotherapie
193
340
.
Erik Johnsen & Rune A. Kroken. (2012) Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness. Therapeutic Advances in Chronic Disease 3:6, pages 287-300.
Crossref
Crossref